CRDL:NASDAQCardiol Therapeutics Inc. Analysis

Cardiol Therapeutics trades at $1.06, well below its 20‑day ($1.14), 50‑day ($1.28) and 200‑day ($1.11) simple moving averages, indicating a technical weakness. The RSI of 33 signals oversold conditions, yet the MACD histogram remains negative and the MACD line sits just under its signal, reinforcing a bearish momentum. On the fundamentals side, the company reports zero revenue, a -$35.6M EBITDA, and a cash burn of roughly $13M in free cash flow, while its price‑to‑book ratio of 6.95 is far above the book value per share of $0.15. Volatility is elevated at 36.8% over the past 30 days and a beta of 1.23 suggests the stock moves more aggressively than the market. Despite these red flags, analyst targets imply a 572% upside, and the Fear‑Greed Index reads “Extreme Greed,” reflecting strong speculative sentiment.
Given the combination of weak technical signals, a cash‑intensive clinical‑stage business model, and a market that appears overly optimistic, investors should treat CRDL as a high‑risk, high‑potential play that currently lacks earnings support.